Research
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k119 (Published 06 February 2018) Cite this as: BMJ 2018;360:k119
Data supplement
Web Extra
- Data Supplement - Appendix: Supplementary materials
- Data Supplement - Appendix: Supplementary materials
- Data Supplement - Appendix: Supplementary materials
- Data Supplement - Appendix: Supplementary materials
- Data Supplement - Appendix: Supplementary materials
Web Extra
- Data Supplement - Appendix: Supplementary materials
- Data Supplement - Appendix: Supplementary materials
- Data Supplement - Appendix: Supplementary materials
- Data Supplement - Appendix: Supplementary materials
- Data Supplement - Appendix: Supplementary materials
Related articles
- Research Published: 29 August 2019; BMJ 366 doi:10.1136/bmj.l4772
- Research Published: 25 August 2020; BMJ 370 doi:10.1136/bmj.m2812
- Research Published: 23 September 2020; BMJ 370 doi:10.1136/bmj.m3342
- Research Published: 10 May 2022; BMJ 377 doi:10.1136/bmj-2021-069400
See more
- Type 1 diabetes: Randox removes adverts after claims that it was using fear to sell genetic testBMJ March 25, 2024, 384 q744; DOI: https://doi.org/10.1136/bmj.q744
- FDA approves first over-the-counter blood glucose monitor for diabetesBMJ March 11, 2024, 384 q611; DOI: https://doi.org/10.1136/bmj.q611
- US food manufacturer can say that eating yogurt reduces risk of type 2 diabetes, says FDABMJ March 06, 2024, 384 q569; DOI: https://doi.org/10.1136/bmj.q569
- Scarlett McNally: Preventing obesity is different from curing it—and even more urgentBMJ January 23, 2024, 384 q134; DOI: https://doi.org/10.1136/bmj.q134
- Artificial pancreases for type 1 diabetes: Better access is “watershed moment”—but delivery is keyBMJ January 23, 2024, 384 q102; DOI: https://doi.org/10.1136/bmj.q102
Cited by...
- Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study
- Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study
- Utility of Automated Data-adaptive Propensity Score Method for Confounding by Indication in Comparative Effectiveness Study in Real World Medicare and Registry Data
- Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and stroke outcomes
- Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
- Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
- Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
- Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study
- Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride
- Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
- Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways